Desalkylgidazepam

Desalkylgidazepam is classified as a novel benzodiazepine. Benzodiazepines are central nervous system depressants. Novel benzodiazepines, typically defined as emergent benzodiazepines not used medicinally, are often pirated from early drug discovery or pharmaceutical studies. Novel benzodiazepines have appeared on illicit drug markets in recent years and have caused adverse events, as described in the literature; fatalities linked to novel benzodiazepine use have occurred, commonly when used in combination with other depressants (e.g., opioids and alcohol). Desalkylgidazepam is a metabolite of the prodrug gidazepam but has now emerged on the recreational drug market as a drug on its own. Desalkylgidazepam is structurally similar to nordiazepam. Desalkylgidazepam is not federally controlled in the United States; however, nordiazepam is a Schedule IV drug.

Class:

Benzodiazepine

Appearance:

Blood

Formula:

C15H11BrN2O

MW:

315.2

[M+]:

314

[M+H]+:

315.0128

IUPAC:

7-bromo-5-phenyl-1,3-dihydro-1,4-benzodiazepin-2-one

Report Date:

December 9, 2022